{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:11:04Z","timestamp":1779120664056,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jdermsci.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:43:10Z","timestamp":1776354190000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treg cells as potential therapeutic targets for bullous pemphigoid: A review"],"prefix":"10.1016","volume":"122","author":[{"given":"Honghao","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiguang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9863","key":"10.1016\/j.jdermsci.2026.04.003_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jdermsci.2026.04.003_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2026.04.003_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/1346-8138.15251","article-title":"Role of BP230 autoantibodies in bullous pemphigoid","volume":"47","author":"Shih","year":"2020","journal-title":"J. Dermatol."},{"issue":"10","key":"10.1016\/j.jdermsci.2026.04.003_bib5","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.jid.2024.02.029","article-title":"Single-Cell Profiling Unveils the Inflammatory Heterogeneity within Cutaneous Lesions of Bullous Pemphigoid","volume":"144","author":"Ruan","year":"2024","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.jdermsci.2026.04.003_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110219","article-title":"Single-cell sequencing reveals distinct immune cell features in cutaneous lesions of pemphigus vulgaris and bullous pemphigoid","volume":"263","author":"Hu","year":"2024","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib7","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","article-title":"Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jdermsci.2026.04.003_bib9","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.jdermsci.2026.04.003_bib10","article-title":"What's new in the pathogeneses and triggering factors of bullous pemphigoid","author":"Ujiie","year":"2022","journal-title":"J. Dermatol."},{"issue":"12","key":"10.1016\/j.jdermsci.2026.04.003_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/labinvest.2016.108","article-title":"Macropinocytosis of type XVII collagen induced by bullous pemphigoid IgG is regulated via protein kinase C","volume":"96","author":"Iwata","year":"2016","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archdermatol.2009.331","article-title":"Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects","volume":"146","author":"Wieland","year":"2010","journal-title":"Arch. Dermatol."},{"issue":"11","key":"10.1016\/j.jdermsci.2026.04.003_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jdermsci.2026.04.003_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00317","article-title":"Regulatory T Cell Extracellular Vesicles Modify T-Effector Cell Cytokine Production and Protect Against Human Skin Allograft Damage","volume":"8","author":"Tung","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.jdermsci.2026.04.003_bib15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.jdermsci.2026.04.003_bib16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00403-012-1213-9","article-title":"Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients","volume":"304","author":"Quaglino","year":"2012","journal-title":"Arch. Dermatol. Res"},{"issue":"12","key":"10.1016\/j.jdermsci.2026.04.003_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp. Dermatol."},{"issue":"5","key":"10.1016\/j.jdermsci.2026.04.003_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.04.003_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1496413","article-title":"Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1\/PD-L1 inhibitor","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.jdermsci.2026.04.003_bib20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.jdermsci.2026.04.003_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2026.04.003_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2026.04.003_bib23","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jaci.2018.04.006","article-title":"Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease","volume":"142","author":"Haeberle","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jdermsci.2026.04.003_bib24","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","article-title":"Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects","volume":"142","author":"Muramatsu","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2026.04.003_bib25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3389\/fimmu.2017.01628","article-title":"Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases","volume":"8","author":"Bieber","year":"2017","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.jdermsci.2026.04.003_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2133.2008.08979.x","article-title":"CCL18 is expressed in patients with bullous pemphigoid and parallels disease course","volume":"160","author":"G\u00fcnther","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.jdermsci.2026.04.003_bib27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","article-title":"Plasticity of CD4+ T cell lineage differentiation","volume":"30","author":"Zhou","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jdermsci.2026.04.003_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874108","article-title":"Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients","volume":"13","author":"Alexandre","year":"2022","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2026.04.003_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-6143.2007.02088.x","article-title":"Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts","volume":"8","author":"Xia","year":"2008","journal-title":"Am. J. Transpl."},{"issue":"3","key":"10.1016\/j.jdermsci.2026.04.003_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.jdermsci.2026.04.003_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.molmed.2022.04.010","article-title":"Therapeutic potential of interleukin-2 in autoimmune diseases","volume":"28","author":"Yuan","year":"2022","journal-title":"Trends Mol. Med"},{"issue":"5","key":"10.1016\/j.jdermsci.2026.04.003_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"179","key":"10.1016\/j.jdermsci.2026.04.003_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci. Transl. Med"},{"issue":"9","key":"10.1016\/j.jdermsci.2026.04.003_bib34","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber","year":"2024","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jdermsci.2026.04.003_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jdermsci.2026.04.003_bib36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jaad.2024.08.033","article-title":"Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial","volume":"91","author":"Xue","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib37","doi-asserted-by":"crossref","first-page":"9230","DOI":"10.1038\/s41467-024-53384-1","article-title":"The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials","volume":"15","author":"Silverberg","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib38","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41467-025-68100-w","article-title":"Efficacy and safety of low-dose interleukin 2 for Beh\u00e7et's syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial","volume":"17","author":"Liu","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jdermsci.2026.04.003_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljae266.102","article-title":"729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis","volume":"191","author":"Gooderham","year":"2024","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jdermsci.2026.04.003_bib41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","article-title":"Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms","volume":"42","author":"Spangler","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.04.003_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jdermsci.2026.04.003_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jdermsci.2026.04.003_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"issue":"821","key":"10.1016\/j.jdermsci.2026.04.003_bib46","doi-asserted-by":"crossref","first-page":"eadq9913","DOI":"10.1126\/scitranslmed.adq9913","article-title":"Conversion of pathogenic T cells into functionally stabilized T(reg) cells for antigen-specific immunosuppression in pemphigus vulgaris","volume":"17","author":"Mukai","year":"2025","journal-title":"Sci. Transl. Med"},{"issue":"3","key":"10.1016\/j.jdermsci.2026.04.003_bib47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molmed.2007.01.003","article-title":"Natural regulatory T cells: mechanisms of suppression","volume":"13","author":"Miyara","year":"2007","journal-title":"Trends Mol. Med"},{"issue":"8","key":"10.1016\/j.jdermsci.2026.04.003_bib48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/ijd.16678","article-title":"Efficacy and safety of biological agents for pemphigoid: a systematic review and meta-analysis","volume":"62","author":"Lin","year":"2023","journal-title":"Int J. Dermatol."},{"issue":"3 Pt B","key":"10.1016\/j.jdermsci.2026.04.003_bib49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jid.2021.04.040","article-title":"Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways","volume":"142","author":"Ellebrecht","year":"2022","journal-title":"J. Invest Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2026.04.003_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030730","article-title":"The Balance of Th17 versus Treg Cells in Autoimmunity","volume":"19","author":"Lee","year":"2018","journal-title":"Int J. Mol. Sci."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:38:46Z","timestamp":1779118726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181126000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0923181126000770"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.04.003","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treg cells as potential therapeutic targets for bullous pemphigoid: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}